| Biomarker ID | 1568 |
| PMID | 31060542 |
| Year | 2019 |
| Biomarker | BUB1B; CDC45; CDK1; CENPI; CLSPN; ERCC6L; EXO1; NCAPG; NUSAP1; RAD51; RRM2; |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in PCa (Log 2 Median Centered Intensity) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include (CDK1): Signal transduction, Immune system, Signaling by GPCR, Interleukin-2 signaling pathway, Disease Pathways include (NCAPG): Aurora B signaling |
| Experiment | Normal/ Benign Tissue Vs Primary/Localised Prostate Cancer |
| Type of Biomarker | Diagnostic |
| Cohort | 2 cohorts were used in the dataset.GRASSO Cohort: (GSE35988): 28 Benign, 59 Localised, 35 CRPC;MSKCC Cohort: (GSE21032): 35 normal tissues , 131 Primary cancer, and 19 metastatic PCa; |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | Microarrays |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |